<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study was to assess circulating soluble intercellular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (sICAM-1), soluble vascular cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule-1 (sVCAM-1), and interleukin-1beta (IL-1beta) in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) in order to evaluate their clinical significance </plain></SENT>
<SENT sid="1" pm="."><plain>Seventy patients with untreated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> [21 <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA), nine RA with ringed sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>), 17 RA with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), 11 RAEB in transformation (RAEBt), and 12 <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>)] were included in this study </plain></SENT>
<SENT sid="2" pm="."><plain>Serum levels of sICAM, sVCAM, and IL-1beta were determined at diagnosis using commercially available immunoassays </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, 15 healthy volunteers were studied as a control group </plain></SENT>
<SENT sid="4" pm="."><plain>sICAM, sVCAM, and IL-1beta serum levels were significantly higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients in comparison with the control group (P &lt;0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> showed the highest sICAM, sVCAM, and IL-1beta levels in comparison with other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-related subtypes </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore significantly elevated levels of the studied parameters were detected in high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) in comparison with low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (RA and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) </plain></SENT>
<SENT sid="7" pm="."><plain>IL-1beta was strongly correlated both to sICAM and sVCAM </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion we have provided evidence that increased sICAM and sVCAM serum levels are related to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> severity </plain></SENT>
</text></document>